FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org September 10, 2009 (10.1056/NEJMe0908224)

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

"Policy decisions regarding influenza rest on judgments about the behavior of the virus, the impact of the disease and our ability to interdict its course. But the virus is capricious, the disease elusive, and our remedies imperfect," said a report on the 1976 swine-flu epidemic at Fort Dix.¹

Two peer-reviewed articles now publicly available at NEJM.org, by Greenberg et al. (ClinicalTrials.gov number, NCT00938639 [ClinicalTrials.gov] )² and Clark et al. (NCT00943358 [ClinicalTrials.gov] ),³ describe preliminary data on the immunogenicity of the influenza A (H1N1) 2009 monovalent vaccine. These data have been eagerly anticipated, as governments, public health officials, and other stakeholders respond to . . . [Full Text of this Article]

Source Information

From PATH, Seattle.

This article (10.1056/NEJMe0908224) was published on September 10, 2009, at NEJM.org.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.